New eye drug OLN324 shows promise in early trial for two blinding diseases
Disease control
Completed
This early-phase study tested a new eye injection called OLN324 in 164 adults with either wet age-related macular degeneration (AMD) or diabetic macular edema (DME). The main goal was to check safety and how the drug moves through the body, while also looking for early signs it m…
Phase: PHASE1 • Sponsor: Ollin Biosciences, Inc. • Aim: Disease control
Last updated May 04, 2026 16:17 UTC